CAR-T cell therapy targeting carbohydrates in cancer

Informacje na temat projektu

SweetCAR

Identyfikator umowy o grant: 957512

DOI

10.3030/957512

Projekt został zamknięty

Data podpisania przez KE 10 Sierpnia 2020

Data rozpoczęcia 1 Października 2020

Data zakończenia 30 Kwietnia 2022

Finansowanie w ramach

• EXCELLENT SCIENCE - European Research Council (ERC)

Koszt całkowity

Brak danych

Wkład UE

€ 150 000,00

Koordynowany przez

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 1 - SweetCAR (CAR-T cell therapy targeting carbohydrates in cancer)

Okres sprawozdawczy: 2020-10-01 do 2022-04-30

Podsumowanie kontekstu i ogólnych celów projektu

Major limitations in current immunotherapy success are low antigenicity of targeting antigen and tumor heterogeneity. Hence there is an unmet need for novel antigen targets that could potentially be expressed on many tumor types. Cancer express aberrant cell surface glycosylation patterns compared to normal cells. These tumor-associated carbohydrate-neoantigens can be targeted for tumor cell killing by antibodies and cytotoxic immune cells. We aim to focus on targeting cancer carbohydrate-neoantigens using the chimeric antigen receptor T cell (CAR-T) immunotherapy approach. Current clinical CAR-T cells target mostly soluble tumors using CD19, BCMA and other non-cancer specific antigens that often suffer toxicity and side effects. Our universal anti-carbohydrate CAR-T approach could target many types of carcinomas with high specificity and safety, and could potentially reach patients rapidly. Altogether, our product candidates are expected to translate these living drugs into affordable lifesaving treatment for a large number of individuals with cancer, especially those suffering of devastating untreatable solid tumors.